6 completed, 1 unknown, 1 withdrawn. 3 Not applicable, 3 Phase 3, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 3 | Completed 2, Withdrawn 1 |
| Phase 3 | 3 | Completed 2, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow Lucentis (ranibizumab): new trials by email Literature Review of Lucentis (ranibizumab) trials Research Report on Lucentis (ranibizumab)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD LUBT010 (proposed ranibizumab biosimilar), Lucentis (ranibizumab) - Neovascular Age-related Macular Degeneration | Phase 3 | Completed | Lupin Ltd. | 600 | 2020-09-14 | 2026-01-29 |
| A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD) SB11 (Proposed ranibizumab biosimilar), Lucentis (ranibizumab) - Age-Related Macular Degeneration | Phase 3 | Completed | Samsung Bioepis Co., Ltd. | 705 | 2018-03-14 | 2021-05-21 |
| Treatment of Diabetic Macular Edema With 0.5mg Intraocular Ranibizumab (Lucentis) Lucentis (Ranibizumab) - Age-Related Macular Degeneration | Not applicable | Completed | University of Luebeck | 25 | 2011-10-01 | 2014-07-08 |
| Ranibizumab Short- and Log-term Effects on Retinal Function in wAMD Lucentis (Ranibizumab) - Age-Related Macular Degeneration, Retinal Function | Not applicable | Completed | University of Luebeck | 20 | 2010-10-01 | 2015-04-08 |
| Ranibizumab for Neovascularization in Sickle Cell Retinopathy Ranibizumab - Sickle Cell Anemia, Retinopathy | Not applicable | Withdrawn | Kresge Eye Institute | 2010-01-01 | 2012-09-27 | |
| Evaluation of Ranibizumab in Proliferative Diabetic Retinopathy (PDR) Requiring Vitrectomy Lucentis (ranibizumab) - Proliferative Diabetic Retinopathy | Phase 3 | Unknown | Retina Associates, Kansas City | 40 | 2007-08-01 | 2007-08-15 |
| CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography Lucentis (ranibizumab) - Age-related Macular Degeneration | Phase 1 | Completed | Washington University School of Medicine | 17 | 2007-07-01 | 2018-05-03 |
| Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study) Lucentis (Ranibizumab) - Neovascular Age-Related Macular Degeneration | Phase 2 | Completed | University of Miami | 40 | 2004-08-01 | 2006-06-26 |
Macular Degeneration (5) · Anemia, Sickle Cell (1) · Choroidal Neovascularization (1) · Fanconi Anemia, Complementation Group B (1) · Neovascularization, Pathologic (1) · Retinal Diseases (1)
University of Luebeck (2) · Kresge Eye Institute (1) · Lupin Ltd. (1) · Retina Associates, Kansas City (1) · Samsung Bioepis Co., Ltd. (1) · University of Miami (1) · Washington University School of Medicine (1)
United States (6) · Germany (3) · Hungary (2) · India (2) · Poland (2) · Russia (2) · Bulgaria (1) · Czechia (1) · Slovakia (1) · South Korea (1) · United Kingdom (1)
Salvatore Grisanti, M.D. Prof. (2) · Gregory M Fox, MD (1) · Philip J Rosenfeld, MD, PhD (1) · Rajendra S. Apte, MD, PhD (1) · Se Joon Woo (1) · Vinay Shah, MD (1)
PMID 19376495, PMID 21555610, PMID 33211076, PMID 36520462, PMID 37260074
2017 (1)